Peru’s health sector will purchase half a million tablets of the drug ‘Atazanavir’, widely used in the treatment of over 1800 Peruvians diagnosed with HIV. The new contract represents a reduction of 35% in the price paid for the drug, which previously cost up to 20 times the rate in neighboring countries.
The agreement was reached between pricing specialists and representatives of the US – based pharmaceutical company who owns the patent, Bristol-Myers Squibb. The company’s exclusive patent protection will last through 2019. During these negotiations, the Health ministry also issued a decree, declaring the drug to be a matter of Public Interest, which would have allowed for further reductions through the issue of Obligatory Licences.
This was blocked, however, by the Economy and Trade ministers, along with the Justice Ministry. Despite not being reduced to its lowest possible level, the drug’s new sale price will now be lower than that paid in Chile, Colombia or Mexico. In related comments, the Vice-minister for Tourism and Trade said the Obligatory Licenses route was rejected as they don’t foresee access problems for people, who will receive the drug free of charge. Besides, he said, the Health ministry can afford to pay for the higher cost.
In response, the leader of the Red Peruana de Pacientes y Usuarios (Peruvian Network of Patients and Users), Julio Cruz Requenes, said his organization will continue to fight for greater reductions in the price, allowing the millions of dollars saved to be re-directed towards supporting patients suffering from rare diseases.
Source: La República
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI